In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Avant sells Paul Royalty an interest in Rotarix

Executive Summary

An affiliate of Paul Royalty Fund II will pay up to $61mm for a stake in Avant Immunotherapeutics' net royalties on worldwide sales of Rotarix, an oral rotavirus vaccine that Avant has licensed to GlaxoSmithKline; in most territories the royalty rate will range from 7-10%. Rotavirus is the main cause of acute pediatric diarrhea and dehydration and can be fatal.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies

Advertisement
UsernamePublicRestriction

Register